The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Date results information initially provided
Type of registration
Retrospectively registered

Titles & IDs
Public title
Is stroke neurodegenerative? A longitudinal study of changes in brain volume and cognition following stroke (CANVAS: Cognition And Neocortical Volume After Stroke)
Scientific title
Is stroke neurodegenerative? A longitudinal study of changes in brain volume and cognition following stroke (CANVAS: Cognition And Neocortical Volume After Stroke)
Secondary ID [1] 281988 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ischaemic stroke
288418 0
Alzheimer's disease 288420 0
Condition category
Condition code
Stroke 288770 288770 0 0
Neurological 289315 289315 0 0
Alzheimer's disease

Study type
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
135 ishaemic stroke patients will have an 3 Tesla Magnetic Resonance Imaging (MRI) scan, and undergo cognitive testing, at five time points - baseline; 3 months post-stroke; 1 year post-stroke; 3 years post-stroke; and 5 years post-stroke.. Cognitive tests include the MOCA, HVLT-R, REY Copy, Trails A and B, Cogstate battery, BNT, Token Test, NART, Digit Span, and Digit Symbol tasks.

For each MRI scan, participants will lie down flat, and still, in the scanner, for between 30 minutes (first scan) and 55 minutes (each review scan).
Intervention code [1] 286558 0
Not applicable
Comparator / control treatment
Results for ischaemic stroke patients will be compared against 40 healthy controls, who are matched on sex, age, and vascular risk factors (e.g., smoking, diabetes, cholesterol, hypertension).
Control group

Primary outcome [1] 288906 0
Our primary imaging outcome is brain volume change at 3 months versus 3 years, as measured by 3T MRI. We expect that stroke patients will exhibit greater and more rapid loss of whole brain and hippocampal volume, over time, than controls.

Timepoint [1] 288906 0
3 years post-stroke.
Primary outcome [2] 288907 0
Our primary cognitive outcome is a dementia diagnosis, in a proportion of stroke patients, at 3 years. Cognitive test scores will be reviewed, and participants who are thought to have a dementia will be referred on to appropriate members of Austin Health, who are not part of the research team, for formal neuropsychological assessment.

We expect that loss of brain volume will be associated with subsequent cognitive decline.
Timepoint [2] 288907 0
3 years post-stroke.
Secondary outcome [1] 301322 0
Hippocampal volume at 3 months, as measured by structural magnetic resonance imaging, will be predictive of a dementia diagnosis at 3 years post-stroke. A dementia diagnosis will be made by members of Austin Health, who are not part of the research team.
Timepoint [1] 301322 0
3 years post-stroke.

Key inclusion criteria
Inclusion criteria for the stroke group include:

1. Clinical ischaemic stroke;
2. Aged greater than 18 years;
3. Able to have cognitive testing and MRI scan; and
4. Able to give informed consent.

Inclusion criteria for healthy controls are the same, excluding, of course, the stroke diagnosis.

Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Exclusion criteria for stroke patients and control participants are the same. These include:

1. Significant medical comorbidities precluding participation in cognitive testing, or making survival for 3 years unlikely;

2. Normal exclusion criteria for MRI; e.g., implanted metal, severe claustrophobia;

3. Pre-existing dementia;

4. Pregnancy, as a precaution to prevent exposing them to multiple MRI scans in a 12-month period;

5. People in existing dependent or unequal relationships with any member of research team, to protect against coercion.

Study design
Natural history
Defined population
Statistical methods / analysis

Recruitment status
Active, not recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 630 0
Austin Health - Austin Hospital - Heidelberg
Recruitment hospital [2] 631 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment hospital [3] 632 0
Box Hill Hospital - Box Hill

Funding & Sponsors
Funding source category [1] 286767 0
Government body
Name [1] 286767 0
National Health and Medical Research Council (NHMRC)
Address [1] 286767 0
Level 1
16 Markus Clarke Street,
Canberra, ACT 2601
Country [1] 286767 0
Funding source category [2] 291363 0
Name [2] 291363 0
The Myer Foundation and Sidney Myer Fund
Address [2] 291363 0
Little Lonsdale Street
Melbourne Victoria 8011
Country [2] 291363 0
Funding source category [3] 291364 0
Name [3] 291364 0
J.O. and J.R. Wicking Trust
Address [3] 291364 0
55 Collins Street, Melbourne, VIC 3000
Country [3] 291364 0
Funding source category [4] 291365 0
Name [4] 291365 0
The Collie Trusts
Address [4] 291365 0
55 Collins Street, Melbourne, VIC 3000
Country [4] 291365 0
Primary sponsor type
Austin Health
145 Studley Road, Heidelberg VIC 3084
Secondary sponsor category [1] 285547 0
Name [1] 285547 0
The Florey Institute of Neuroscience and Mental Health
Address [1] 285547 0
Melbourne Brain Centre, 245 Burgundy St, Heidelberg 3084
Country [1] 285547 0

Ethics approval
Ethics application status
Ethics committee name [1] 288832 0
Austin Health Human Research Ethics Committee
Ethics committee address [1] 288832 0
Office for Research
145 Studley Road,
Heidelberg, VIC 3084
Ethics committee country [1] 288832 0
Date submitted for ethics approval [1] 288832 0
Approval date [1] 288832 0
Ethics approval number [1] 288832 0
Ethics committee name [2] 288833 0
Melbourne Health Human Research Ethics Committee
Ethics committee address [2] 288833 0
Office for Research
6 East, Central Building
The Royal Melbourne Hospital
300 Grattan Street
Ethics committee country [2] 288833 0
Date submitted for ethics approval [2] 288833 0
Approval date [2] 288833 0
Ethics approval number [2] 288833 0
Ethics committee name [3] 289164 0
Eastern Health Human Research Ethics Committee
Ethics committee address [3] 289164 0
5 Arnold Street, Box Hill
Victoria 3128
Ethics committee country [3] 289164 0
Date submitted for ethics approval [3] 289164 0
Approval date [3] 289164 0
Ethics approval number [3] 289164 0

Brief summary
Stroke and dementia are two of the most common and disabling conditions worldwide, responsible for an enormous and growing burden of disease. There is increasing awareness that the two conditions are linked, with cognitive impairment and dementia common after stroke, vascular dementia accounting for about one-fifth of all dementia cases and recent evidence on the contribution of vascular risk factors to Alzheimer’s disease. Yet we still know very little about whether brain volume loss – a hallmark of dementia – occurs after stroke, and whether such atrophy is related to cognitive decline.

The aim of this research is to establish whether stroke patients have reductions in brain volume in the first three years post-stroke compared to control subjects, and whether regional and global brain volume change is associated with post-stroke dementia in order to elucidate potential causal mechanisms (including genetic markers, amyloid deposition and vascular risk factors).

We hypothesise that stroke patients will exhibit greater brain volume loss than comparable cohorts of stroke-free controls, and further, that stroke patients who develop dementia will exhibit greater global and regional brain volume loss than those who do not dement.

An understanding of whether stroke is neurodegenerative, and in which patients, may be used to help guide the early delivery of disease-modifying therapies.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 37986 0
Prof Amy Brodtmann
Address 37986 0
Melbourne Brain Centre
245 Burgundy Street,
Heidelberg, VIC 3084
Country 37986 0
Phone 37986 0
+61 3 9035 7004
Fax 37986 0
+61 3 9035 7304
Email 37986 0
Contact person for public queries
Name 37987 0
Dr Laura Bird
Address 37987 0
Melbourne Brain Centre
245 Burgundy Street,
Heidelberg, VIC 3084
Country 37987 0
Phone 37987 0
+61 3 9035 7086
Fax 37987 0
+61 3 9035 7304
Email 37987 0
Contact person for scientific queries
Name 37988 0
Prof Amy Brodtmann
Address 37988 0
Melbourne Brain Centre
245 Burgundy Street,
Heidelberg, VIC 3084
Country 37988 0
Phone 37988 0
+61 3 9035 7004
Fax 37988 0
+61 3 9035 7304
Email 37988 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
What data in particular will be shared?
Any demographic, medical, cognitive and MRI data collected at the 5-year review session for stroke participants and healthy controls will be uploaded to an online database.
When will data be available (start and end dates)?
Data collection for the 5-year time-point will be complete in December 2020. We anticipate that 5-year data will be made available 12 months after we have published the main findings relating to this data point. We have not set an end date at this stage.
Available to whom?
The data will only be made available to researchers who provide a methodologically sound proposal.
Available for what types of analyses?
Researchers can perform any analyses that achieve the aims in the approved proposal.
How or where can data be obtained?
Data will be uploaded to an online database. Researchers whose proposals have been approved by the CANVAS study committee will be provided with a web address and login details.
What supporting documents are/will be available?
No other documents available
Summary results
Have study results been published in a peer-reviewed journal?
Journal publication details
Publication date and citation/details [1] 1205 0
Li, Q., Pardoe, H., Lichter, R., Werden, E., Raffelt, A., Cumming, T., & Brodtmann, A. (2014). Cortical thickness estimation in longitudinal stroke studies: A comparison of 3 measurement methods. NeuroImage. Clinical, 8, 526-35. doi:10.1016/j.nicl.2014.08.017
Attachments [1] 1205 0
Publication date and citation/details [2] 1206 0
Khlif, M.S., Egorova, N., Werden, E. et al. (2018). A comparison of automated segmentation and manual tracing in estimating hippocampal volume in ischemic stroke and healthy control participants. Neuroimage: Clinical (22 October 2018):
Attachments [2] 1206 0
Publication date and citation/details [3] 1207 0
Werden, E., et al. Brodtmann, A. (2017). Structural MRI markers of brain aging early after ischemic stroke. Neurology, 89 (2): 116-124. doi: 10.1212/WNL.0000000000004086. Epub 2017 Jun 9.
Attachments [3] 1207 0
Publication date and citation/details [4] 1208 0
Veldsman, M., Werden, E., et al., Brodtmann, A. (2017). Default mode network neurodegeneration reveals the remote effects of ischaemic stroke. Journal of Neurology, Neurosurgery, and Psychiatry, 89: 318-320. doi: 10.1136/jnnp-2017-315676. Epub 2017 Jul 26.
Attachments [4] 1208 0
Publication date and citation/details [5] 1209 0
Physical activity after stroke is associated with increased interhemispheric connectivity of the dorsal attention network. Neurorehabilitation and Neural Repair, 31, 157-167. doi: 10.1177/1545968316666958. Epub 2016 Sep 24.
Attachments [5] 1209 0
Publication date and citation/details [6] 1210 0
N Egorova, T Cumming, C Shirbin, M Veldsman, E Werden, A Brodtmann (2018). Lower cognitive control network connectivity in stroke participants with depressive features. Translational Psychiatry 7 (11), 4.
Attachments [6] 1210 0
Publication date and citation/details [7] 1211 0
Egorova N., Veldsman M., Cumming T., Brodtmann A. (2017). Fractional amplitude of low-frequency fluctuations (fALFF) in post-stroke depression. NeuroImage: Clinical 16, 116-124. doi: 10.1016/j.nicl.2017.07.014. eCollection 2017.
Attachments [7] 1211 0
Publication date and citation/details [8] 7053 0
Werden, E., Khlif, M. S., Bird, L. J., Cumming, T., Bradshaw, J., Khan, W., …& Brodtmann, A. (2019). APOE E4 carriers show delayed recovery of verbal memory and smaller entorhinal volume in the first year after ischemic stroke. Journal of Alzheimer’s Disease, Pre-press, 1-15. doi: 10.3233/JAD-190566
Attachments [8] 7053 0
Publication date and citation/details [9] 7054 0
Khlif, M. S., Werden, E., Egorova, N., Boccardi, M., Redolfi, A., Bird, L.., & Brodtmann, A. (2019). Assessment of longitudinal hippocampal atrophy in the first year after ischemic stroke using automatic segmentation techniques. NeuroImage: Clinical, Pre-print. doi: 10.1016/j.nicl.2019.102008
Attachments [9] 7054 0
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary